ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1465	National Cancer Institute	Html	en	Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of childhood acute myeloid leukemia, myelodysplastic syndromes, and other myeloproliferative disorders.	cytogenetically normal AML 0.472151 acute myelogenous leukemia 0.566998 acute myeloid leukemias 0.479592 acute leukemia cells 0.490369 Mixed-phenotype acute leukemia 0.492893 pediatric AML chromosomal 0.458451 acute leukemias 0.458907 mutations 0.522652 myeloid leukemia patients 0.500607 leukemia group 0.471134 biphenotypic acute leukemia 0.49298 children 0.465 pediatric myeloid leukemia 0.49349 childhood AML 0.456416 chronic myelomonocytic leukemia 0.469481 AML 0.543947 World Health Organization 0.492048 CEBPA mutations 0.477251 leukemia development 0.468848 acute monocytic leukemia 0.483805 chronic myelogenous leukemia 0.468404 Acute myelomonocytic leukemia 0.489711 prognostic significance 0.496134 international retrospective study 0.454979 promyelocytic leukemia cases 0.462082	pediatric leukemia 0.454781 pediatric AML patients 0.456596 et al. 0.655126 acute megakaryoblastic leukemia 0.509773 normal pediatric AML 0.45551 myeloid neoplasms 0.47963 internal tandem duplication 0.460861 Br J Haematol 0.501425 acute promyelocytic leukaemia 0.457345 normal myeloid development 0.457734 acute myeloid leukemia 0.996934 acute myeloid leukaemia 0.513022 Leukemia Study Group 0.464981 juvenile myelomonocytic leukemia 0.495899 myeloid leukemia cells 0.495298 acute megakaryocytic leukemia 0.484055 mixed lineage leukemia 0.460628 Abstract 0.599778 Clin Oncol 0.480965 AML patients 0.464901 blood 0.501248 promyelocytic leukemia correlates 0.463064 acute promyelocytic leukemia 0.625964 pediatric AML 0.496596	CLICK HERE
1506	National Cancer Institute	Html	en	Uterine Sarcoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of uterine sarcomas.	carcinosarcomas 0.527692 preceding study 0.294778 ongoing clinical trial 0.328334 higher response rate 0.443879 second-line therapy 0.320988 GOG-87B trial 0.302772 combination arm 0.302761 parallel endometrial cancer 0.512209 antitumor activity 0.3101 overall survival 0.306973 wrong pathology 0.309304 randomized comparison 0.315064 combination 0.391895 GOG-108 trial 0.299664 patients 0.983458 response rate 0.846539 toxic 5-day regimen 0.481752 epidemiologic features 0.339925 recurrent disease 0.339729 endometrial stromal cell 0.349768 homologous elements 0.328462 Gynecologic Oncology Group 0.655599 stromal components 0.337885 prior radiation therapy 0.439727 radiation therapy 0.469225	evaluable patients 0.303784 vs 0.355238 study 0.345019 postmenopausal predominance 0.341262 longer progression-free survival 0.464996 heterologous elements 0.32327 Carcinosarcomas parallel endometrial 0.494212 stromal cell sarcomas 0.343743 endometrial adenocarcinomas 0.337476 separate trials 0.29781 cisplatin 0.316026 first-line therapy 0.436639 significant improvement 0.309111 uterine sarcoma 0.513207 therapy 0.475954 follow-up GOG-0161 0.313043 response rates 0.291195 chemotherapy studies 0.29709 modality approaches 0.330804 partial response rate 0.446598 uterine sarcomas 0.312583 hazard ratio 0.311967 confidence interval 0.314154 striated muscle 0.341592	CLICK HERE
1588	National Cancer Institute	Html	en	Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood soft tissue sarcomas.	Plexiform fibrohistiocytic tumor 0.280012 malignant tumor cells 0.307621 cancer treatment 0.290865 soft tissue cell 0.275637 rare tumor 0.289328 Inflammatory myofibroblastic tumor 0.282045 childhood soft tissue 0.441268 cell tumor 0.287204 body 0.349975 type 0.32132 PDQ cancer information 0.285649 children 0.277658 clinical trials 0.413146 clinical trial 0.299958 clear cell sarcoma 0.298146 Malignant triton tumor 0.279981 blood vessels 0.296075 smooth muscle tumor 0.277296 lymph nodes 0.29136 radiation therapy 0.449797 soft tissue sarcoma 0.971932 cartilage tumor 0.284625 treatment 0.443484 synovial sarcoma 0.284633	Primitive neuroectodermal tumor 0.276261 nerve sheath tumor 0.323482 chromosome switches places 0.389422 cancer cells 0.417787 tumor cells 0.415668 tumor suppressor gene 0.277153 genetic change 0.398935 soft tissue sarcomas 0.289965 /extraskeletal Ewing tumor 0.27615 fibrous tissue tumor 0.342556 tissue sarcoma cells 0.300511 primary tumor 0.287542 metastatic tumor 0.275814 following types 0.304501 soft tissue tumors 0.283665 PDQ summary 0.323186 tumors 0.289287 tumor 0.552574 Tissue Sarcoma Treatment 0.342732 certain genetic change 0.378247 cancer 0.496155 information 0.290056 Adult Soft Tissue 0.29745 fast-growing tumor 0.287416	CLICK HERE
1745	National Cancer Institute	Html	en	Radon and Cancer	A fact sheet about radon, an odorless radioactive gas, and its possible association with cancer, and how to test for radon in the home.	residential radon 0.562353 American case-control studies 0.256996 lung cancer 0.983232 radon test kit 0.445489 homes 0.263005 tiny radioactive particles 0.260576 radon risk 0.437726 indoor radon levels 0.492199 Lubin JH 0.260179 lung tumors 0.286182 long-term tests 0.254643 residential radon exposure 0.479323 average radon level 0.4525 slightly increased risk 0.263122 experimental animal studies 0.260434 radon gas 0.490329 radon programs 0.421637 radon exposure 0.485254 Environmental Protection Agency 0.303434 National Radon Hotline 0.443169 Radon Reduction 0.421521 radon testing 0.473889 radon 0.847228 National Radon 0.44518	United States 0.325125 radon causes lung 0.520748 radioactive gas 0.261736 high radon levels 0.476793 U.S. Environmental Protection 0.30233 underground uranium miners 0.261056 radon mitigation promotion 0.443958 normal decay 0.26025 low levels outdoors 0.269932 radon studies 0.441219 highest radon levels 0.486865 German uranium miners 0.256763 different indoor radon 0.45539 radioactive particles 0.292648 radon levels 0.737469 Health Physics 0.256943 Radon Program Services 0.446453 radon-related cancer deaths 0.313801 lung cancer deaths 0.435124 lung cancer risk 0.337519 local radon official 0.450897 elements uranium 0.296591 National Radon Hotlines 0.444919 et al 0.254717	CLICK HERE
1962	National Cancer Institute	Html	es	Tratamiento de las neoplasias mielodisplásicas o mieloproliferativas (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de las neoplasias mielodisplásicas o mieloproliferativas, incluso las leucemias mielomonocíticas crónicas o juveniles, y la LMC atípica.	siguientes procedimientos 0.310473 células madre 0.796441 cuidado médico 0.302013 leucemia aguda 0.308416 células madre formadoras 0.309431 hueso compacto 0.314757 enlace drugs approved 0.312251 cromosoma filadelfia 0.309322 célula madre mieloide 0.313237 células anormales.ampliar aspiración 0.315092 National Cancer Institute 0.302184 siguientes riesgos 0.301804 leucemia mielomonocítica 0.520866 Instituto Nacional 0.307834 célula madre linfoide 0.331173	PDQ Tratamiento 0.305968 neurofibromatosis tipo 0.303576 células madre mieloide 0.322767 leucemia mielógena 0.392932 neoplasias mielodisplásicas 0.970229 Physician Data Query 0.30823 neoplasia mielodisplásica 0.36973 Myeloproliferative Neoplasms 0.306895 siguientes enlaces 0.302219 célula madre 0.398378 células sanguíneas maduras 0.374442 neoplasias mieloproliferativas 0.31703 ósea elabora células 0.32181 siguientes pruebas 0.312083 siguientes sumarios 0.307642	CLICK HERE
3431	National Cancer Institute	Html	es	Dietilestilbestrol (DES) y el cáncer	Hoja informativa sobre el DES (una versión sintética del estrógeno) y los problemas de salud en los niños que estuvieron expuestos al DES en la matriz.	hormona femenina estrógeno 0.312636 Hatch EE 0.454515 DES problemas 0.383286 Urogenital abnormalities 0.305699 Diethylstilbestrol contraindicated 0.311242 exposed to diethylstilbestrol 0.406175 Cell Cancer Registry 0.312383 British Journal 0.315496 defectos congénitos 0.317789 reproductive characteristics 0.305946 Noller KL 0.315866 related synthetic hormones 0.309521 Prenatal diethylstilbestrol 0.312976 diethylstilbestrol during pregnancy 0.315088 Environmental Health 0.313238 posibles efectos 0.334954 Internal Medicine 0.305939 Estados Unidos 0.328505 DES Follow-up Study 0.443119 abortos espontáneos 0.319323 NCI Mamografías 0.30661 resultados contradictorios 0.314367 long-term health effects 0.309445 PubMed Abstract 0.959102 International Journal 0.31496	Cancer Control 0.307472 Carcinogénesis Hormonal Transplacentaria 0.310163 DES daughters 0.375119 given diethylstilbestrol 0.321239 cohort study 0.315559 Titus-Ernstoff L 0.382214 Hormonal Transplacental Carcinogenesis 0.31001 mayores riesgos 0.313929 Environmental Health Sciences 0.309128 Troisi R 0.359524 Hoover RN 0.313827 stilbestrol therapy with 0.308895 FDA Drug Bulletin 0.308403 to diethylstilbestrol alters 0.318831 Verloop J 0.312608 cuello uterino 0.526442 Public Relations Committee 0.308493 exposed prenatally 0.313265 to des 0.379155 riesgos instantáneos porcentaje 0.310067 menopausia prematura 0.316803 to diethylstilbestrol 0.546373 New England Journal 0.327355 DES Porcentaje 0.382487	CLICK HERE
3451	National Cancer Institute	Html	en	Planning the Transition to End-of-Life Care in Advanced Cancer (PDQ®)–Patient Version	Expert-reviewed information summary about the preparation needed by health care providers, patients, and families for the transition to end-of-life care in advanced cancer.	CPR 0.551685 end-of-life decisions 0.505947 treatments 0.539675 PDQ cancer information 0.625539 Out-of-hospital DNR order 0.511763 health care team 0.497649 clinical trials 0.511926 wishes 0.516111 health care providers 0.549541 emergency medical workers 0.548212 cancer information summary 0.569329 health care professionals 0.505787 family members 0.526957 patients 0.489953 end-of-life care options 0.519094 symptoms 0.496271 NCI PDQ cancer 0.514682 new chemotherapy treatment 0.48923 doctors 0.602249 supportive care 0.525701 life-saving procedures 0.497748 care 0.924816 end-of-life care 0.782032 treatment 0.671878	DNR order 0.576468 Palliative Care Organization 0.500652 breathing stops 0.496404 palliative care 0.693314 Cancer Information Service 0.494158 Health care proxy 0.49362 cardiopulmonary resuscitation 0.54384 hospice care 0.526131 National Cancer Institute 0.571506 decisions 0.647069 Advance directives 0.611485 health care 0.652677 Palliative Care Editorial 0.541845 advanced cancer 0.542943 Cancer Care page 0.510244 Care Editorial Board 0.540113 PDQ summary 0.57393 doctor 0.567646 end stages 0.495403 breathing machine 0.491509 cancer information summaries 0.492454 comprehensive cancer information 0.492895 cancer 0.776389 information 0.649786	CLICK HERE
3526	National Cancer Institute	Html	es	Dosis altas de vitamina C (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos sobre el uso de dosis altas de vitamina C como tratamiento para personas con cáncer.	cuerpo capta 0.40884 Centro Nacional 0.415435 trastornos renales 0.409265 New Hampshire Avenue 0.4108 voluntarios sanos 0.40968 Drug Administration 0.406678 NCI Best Case 0.417317 vía oral 0.410816 datos bibliográficos pubmed 0.411428 Ewan Cameron 0.409689 siguientes preguntas 0.406272 modelo murino 0.409716 PDQ Dosis 0.435611 químico linus pauling 0.417313 vitamina c 0.94266 National Cancer Institute 0.412764 siguientes riesgos 0.407804 Instituto Nacional 0.459849 quimio terapia 0.40979	premio nobel 0.409373 Salud Complementaria 0.42125 medicamento bortezomib 0.415099 Visuals Online 0.407849 complementarias revisa 0.410331 pequeñas cantidades 0.408757 Physician Data Query 0.445061 Estados Unidos 0.504589 cálculos renales 0.409375 libre uso 0.407317 cabo estudios 0.435571 claro cuánto 0.409653 página manejo 0.407381 ¿El tratamiento 0.414934 ¿Los beneficios 0.406643 juntos cam 0.406416 Series Program 0.406643 medicina complementaria 0.607291	CLICK HERE
3606	National Cancer Institute	Html	en	Bioinformatics and Cancer	Researchers take on challenges and opportunities to mine	analytical tools 0.503896 data 0.930485 complex biological questions 0.5412 computational tools 0.425959 research 0.765612 research program 0.461031 precision medicine—that 0.427901 Cancer Informatics Program 0.53792 primary data 0.493101 research community 0.640856 comprehensive molecular analyses 0.497733 cancer research data 0.639487 researchers 0.498144 molecular characteristics 0.432662 Big Data 0.513141 NCI’s Center 0.486223 NCI-funded studies 0.438225 NCIP Hub 0.491716 commercial cloud providers 0.498944 cloud technology 0.483618 Genome Research Institute 0.551547 cancer research community 0.589113 access 0.431106 numerous research areas 0.554113 imaging studies 0.432684	NCI-funded research 0.466881 cancer research 0.762444 healthy tissue samples 0.490086 data clouds 0.491108 NCI’s TARGET 0.476821 TCGA-collected data 0.483444 Genomic Data Sharing 0.579305 molecular data 0.478795 multi-investigator research teams 0.550054 different technological platforms 0.513272 studies 0.49641 translational studies 0.42911 sheer volume 0.427853 NCI Cancer Genomics 0.60107 cancer researchers 0.462047 cancer genomics repository 0.530232 biological data 0.643746 clinical care 0.431785 different tools 0.428018 Cancer Genome Atlas 0.527253 biomedical research 0.47962 cancer research projects 0.699979 potential new targets 0.495536 NCI Genomic Data 0.63374	CLICK HERE
16473	National Cancer Institute	Html	en	Nivolumab Improves Survival for Patients with Recurrent Head and Neck Cancer	A summary of clinical trial results showing that nivolumab (Opdivo®) improved overall survival compared with standard chemotherapy in patients with head and neck squamous cell carcinoma.	platinum-based chemotherapy 0.436007 immune checkpoint inhibitor 0.707571 pembrolizumab block 0.240544 checkpoint inhibitor nivolumab 0.489462 standard therapy group 0.856853 HNSCC tumor growth 0.401684 squamous cells 0.272124 Cancer Therapy Evaluation 0.372634 overall survival 0.94063 broader group 0.255871 poor prognoses 0.250488 median progression-free survival 0.452131 Pittsburgh Medical Center 0.399432 Maura L. Gillison 0.401307 Bristol-Myers Squibb 0.274378 median overall survival 0.493854 patients 0.514717 metastatic HNSCC 0.274208 HNSCC 0.412159 effective second-line therapy 0.394916 Shakun Malik 0.250672 Drug Administration 0.252661 cancer cells 0.262643 treatment-related adverse events 0.35048	Human papillomavirus 0.256631 better treatment 0.263098 unacceptable side effects 0.245803 median follow-up 0.28334 PD-L1—a molecule 0.240638 nivolumab group 0.622355 tumor cells 0.248287 new trial 0.243059 standard chemotherapy 0.417786 Ohio State University 0.396086 median length 0.283635 immune cells 0.271394 salivary glands 0.258435 nasal passages 0.247938 Robert L. Ferris 0.397098 Cancer Institute 0.278018 neck cancer 0.259993 tumor response 0.240293 common adverse events 0.34039 New England Journal 0.393835 oral cavity 0.246829 checkpoint molecule PD-1 0.389662 Earlier studies 0.247274 phase III trial 0.261728	CLICK HERE